[[Image:Allergy degranulation processes 01.svg|thumb|Degranulation processes 1 - antigen; 2 - IgE antibody; 3 - FcεRI receptor; 4 - preformed mediators (histamine, proteases, chemokines, heparin); 5 - granules; 6 - mast cell; 7 - newly formed mediators (prostaglandins, leukotrienes, thromboxanes, PAF)]]
Immunoglobulin E (IgE) is a type of [[antibody]] (or [[immunoglobulin]] (Ig) "[[isotype (immunology)|isotype]]") that has been found only in [[mammal]]s. IgE is synthesised by [[plasma cell]]s. Monomers of IgE consist of two heavy chains (ε chain) and two light chains, with the ε chain containing 4 Ig-like constant domains (Cε1-Cε4). IgE's main function is immune system|immunity
to parasites such as helminth
s like ''Schistosoma mansoni
'', ''Trichinella spiralis
'', and ''Fasciola hepatica
''. IgE is utilized during immune defense against certain protozoa
s such as ''Plasmodium falciparum
IgE may have evolved as a last line of defense to protect against venoms.
IgE also has an essential role in type I hypersensitivity
, which manifests in various allergic diseases, such as allergic asthma
, most types of sinusitis
, allergic rhinitis
, food allergies, and specific types of chronic urticaria
and atopic dermatitis
. IgE also plays a pivotal role in responses to allergens, such as: anaphylactic
reactions to drugs, bee stings, and antigen preparations used in desensitization immunotherapy
Although IgE is typically the least abundant isotype—blood serum
IgE levels in a normal ("non-atopic
") individual are only 0.05% of the Ig concentration, compared to 75% for the IgGs
at 10 mg/ml, which are the isotypes responsible for most of the classical adaptive immune response
—it is capable of triggering the most powerful inflammatory reactions.
IgE was simultaneously discovered in 1966 and 1967 by two independent groups: Kimishige Ishizaka
and his wife Teruko Ishizaka
at the Children's Asthma Research Institute and Hospital in Denver
, and by S.G.O Johansson and Hans Bennich in Uppsala
Their joint paper was published in April 1969.
IgE primes the IgE-mediated allergic response by binding to Fc receptor
s found on the surface of mast cell
s and basophil
s. Fc receptors are also found on eosinophil
s and platelet
s in humans. There are two types of Fcε receptors:
(type I Fcε receptor), the high-affinity IgE receptor
(type II Fcε receptor), also known as CD23, the low-affinity IgE receptor
IgE can upregulate the expression of both types of Fcε receptors. FcεRI is expressed on mast cell
, and the antigen-presenting dendritic cells
in both mice and humans. Binding of antigen
s to IgE already bound by the FcεRI on mast cells causes cross-linking of the bound IgE and the aggregation of the underlying FcεRI, leading to degranulation
(the release of mediators from the cells) and the secretion of several types of type 2 cytokines like IL-3 and Stem Cell Factor (SCF) which both help the mast cells survive and accumulate in tissue, IL-4, IL-5 and IL-13 as well as IL-33 which in turn activate group 2-innate lymphoid cells (ILC2, or natural helper cells). Basophils, which share a common haemopoietic progenitor with mast cells, upon the cross-linking of their surface bound IgE by antigens, also release type 2 cytokine
s like interleukin-4
(IL-4) and interleukin-13
(IL-13) and other inflammatory mediators. The low-affinity receptor (FcεRII) is always expressed on B cell
s; but IL-4 can induce its expression on the surfaces of macrophage
s, and some T cell
There has been an accumulating evidence in the past decade on the physiological role of IgE: this isotype has co-evolved with basophils and mast cells in the defence against parasites like helminths (like Schistosoma) but may be also effective in bacterial infections.
Epidemiological research shows that IgE level is increased when infected by ''Schistosoma mansoni'', ''Necator americanus
in humans. It is most likely beneficial in removal of hookworms from the lung.
Toxin hypothesis of allergic disease
In 1981 Margie Profet
suggested that allergic reactions have evolved as a last line of defense to protect against venoms
Although controversial at the time, new work supports some of Profet’s thoughts on the adaptive role of allergies as a defense against noxious toxins.
In 2013 it emerged that IgE-antibodies play an essential role in acquired resistance to honey bee
and Russell's viper
The authors conclude that "a small dose of bee venom conferred immunity to a much larger, fatal dose" and "this kind of venom-specific, IgE-associated, adaptive immune response developed, at least in evolutionary terms, to protect the host against potentially toxic amounts of venom, such as would happen if the animal encountered a whole nest of bees, or in the event of a snakebite".
The major allergen of bee venom (phospholipase A2) induces a Th2 immune responses, associated with production of IgE antibodies, which may "increase the resistance of mice to challenge with potentially lethal doses".
Although it is not yet well understood, IgE may play an important role in the immune system's recognition of cancer
, in which the stimulation of a strong cytotoxic response against cells displaying only small amounts of early cancer markers would be beneficial. If this were the case, anti-IgE treatments such as omalizumab
(for allergies) might have some undesirable side effects. However, a recent study, which was performed based on pooled analysis using comprehensive data from 67 phase I to IV clinical trials of omalizumab in various indications, concluded that a causal relationship between omalizumab therapy and malignancy is unlikely.
Role in disease
individuals can have up to ten times the normal level of IgE in their blood (as do sufferers of hyper-IgE syndrome
). However, this may not be a requirement for symptoms to occur as has been seen in asthmatics with normal IgE levels in their blood—recent research has shown that IgE production can occur locally in the nasal mucosa.
IgE that can specifically recognise an allergen
(typically this is a protein, such as dust mite Der p 1
, cat Fel d 1
, grass or ragweed
pollen, etc.) has a unique long-lived interaction with its high-affinity receptor
FcεRI so that basophils
and mast cells
, capable of mediating inflammatory reactions, become "primed", ready to release chemicals like histamine
s, and certain interleukins. These chemicals cause many of the symptoms we associate with allergy, such as airway constriction in asthma
, local inflammation in eczema
, increased mucus
secretion in allergic rhinitis
, and increased vascular permeability, it is presumed, to allow other immune cells to gain access to tissues, but which can lead to a potentially fatal drop in blood pressure as in anaphylaxis
IgE is known to be elevated in various autoimmune disorders such as SLE
, rheumatoid arthritis
(RA), and psoriasis
, and is theorized to be of pathogenetic importance in SLE and RA by eliciting a hypersensitivity reaction.
Regulation of IgE levels through control of B cell differentiation to antibody-secreting plasma cells
is thought to involve the "low-affinity" receptor FcεRII, or CD23
may also allow facilitated antigen presentation, an IgE-dependent mechanism whereby B cells
are able to present allergen to (and stimulate) specific T helper cells
, causing the perpetuation of a Th2 response, one of the hallmarks of which is the production of more antibodies.
Role in diagnosis
Diagnosis of allergy is most often done by reviewing a person's medical history and finding a positive result for the presence of allergen specific IgE when conducting a skin or blood test.
Specific IgE testing is the proven test for allergy detection; evidence does not show that indiscriminate IgE testing or testing for immunoglobulin G (IgG) can support allergy diagnosis.
Drugs targeting the IgE pathway
Currently, allergic diseases and asthma are usually treated with one or more of the following drugs: (1) antihistamines
s, which antagonize the inflammatory mediators histamine and leukotrienes, (2) local or systemic (oral or injectable) corticosteroids
, which suppress a broad spectrum of inflammatory mechanisms, (3) short or long-acting bronchodilators
, which relax smooth muscle of constricted airway in asthma, or (4) mast cell stabilizer
s, which inhibit the degranulation
of mast cells that is normally triggered by IgE-binding at FcεRI
. Long-term uses of systemic corticosteroids are known to cause many serious side effects and are advisable to avoid, if alternative therapies are available.
IgE, the IgE synthesis pathway, and the IgE-mediated allergic/inflammatory pathway are all important targets in intervening with the pathological processes of allergy, asthma, and other IgE-mediated diseases. The B lymphocyte differentiation and maturation pathway that eventually generate IgE-secreting plasma cells go through the intermediate steps of IgE-expressing B lymphoblasts and involves the interaction with IgE-expressing memory B cells. Tanox
, a biotech company based in Houston, Texas, proposed in 1987 that by targeting membrane-bound IgE (mIgE) on B lymphoblast and memory B cells, those cells can be lysed or down-regulated, thus achieving the inhibition of the production of antigen-specific IgE and hence a shift of immune balance toward non-IgE mechanisms.
Two approaches targeting the IgE pathway were evolved and both are in active development. In the first approach, the anti-IgE
antibody drug omalizumab
(trade name Xolair
) recognises IgE not bound to its receptors and is used to neutralise or mop-up existing IgE and prevent it from binding to the receptors on mast cells and basophils. Xolair has been approved in many countries for treating severe, persistent allergic asthma. It has also been approved in March 2014 in the European Union and the U. S. for treating chronic spontaneous urticaria
, which cannot be adequately treated with H1-antihistamines
. In the second approach, antibodies specific for a domain of 52 amino acid residues, referred to as CεmX or M1’ (M1 prime), present only on human mIgE on B cells and not on free, soluble IgE, have been prepared and are under clinical development for the treatment of allergy and asthma.
An anti-M1’ humanized antibody, quilizumab
, is in phase IIb clinical trial.
In 2002, researchers at The Randall Division of Cell and Molecular Biophysics
determined the structure of IgE.
Understanding of this structure (which is atypical of other isotypes in that it is highly bent and asymmetric) and of the interaction of IgE with receptor FcεRI will enable development of a new generation of allergy drugs that seek to interfere with the IgE-receptor interaction. It may be possible to design treatments cheaper than monoclonal antibodies (for instance, small molecule drugs) that use a similar approach to inhibit binding of IgE to its receptor.
Slide presentation of Degranulation processes